Search
Arformoterol
go.drugbank.com/drugs/DB01274ApprovedThe use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients … using long-acting beta agonists for the treatment of asthma.
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line … This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure
Categories: Antivirals for treatment of HCV infectionsAmifampridine
go.drugbank.com/drugs/DB11640ApprovedFirdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigationalPalopegteriparatide is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol carrier (mPEG) via a proprietary TransCon Linker. … [A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, )-peptide of parathyroid hormone (Homo sapiens parathMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalby a reduced number of mature neutrophils and lymphocytes. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Bifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Strontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnStrontium chloride (SrCl2) is a salt of strontium and chloride. … SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168].
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].
Categories: combinations of tetracyclinesEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalEfbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.